Dr. Luo is a clinician-investigator and general internist whose research focuses on prescription drug use, pricing, policy, and comparative effectiveness. he is especially interested in medicines for chronic diseases such as diabetes, including insulin. Prior to joining the Pitt faculty, he was a faculty member at Harvard Medical School and the Brigham and Women's Hospital in Boston.
Dr. serves as PI on a trial comparing human versus analogue insulin for youth with type 1 diabetes living in low resource settings (HumAn-1). Learn more about this trial. He is also a NIDDK K23 awardee to examine cost-related medication restrictions among adults with type 2 diabetes. His original investigations and perspectives have been published in NEJM, The Lancet, JAMA, JAMA Internal Medicine, and Annals of Internal Medicine. His work has been featured in The Washington Post and VOX News.
If you are interested in working as a trainee or collaborator in his research group, contact Dr. Luo at luoj@pitt.edu.
Dr. Luo also teaching students and residents on the inpatient medicine teaching service at UPMC Presbyterian and enjoys serving as a mentor to students and trainees. His clinical interests are in type 2 diabetes, cardiovascular disease, and chronic pain.
- BS, Duke University, 2006
- Fogarty International Clinical Research Scholars Program, 2010
- MD, University of Illinois at Chicago College of Medicine, 2011
- Internship and Residency, Yale-New Haven Hospital (Primary Care Internal Medicine), 2014
- MPH, Harvard T.H. Chan School of Public Health, 2016
- Fellowship in General Medicine and Primary Care (Research), Brigham and Women’s Hospital, Harvard Medical School, 2016
Education & Training
White GE, Shu I, Rometo D, Arnold J, Korytkowski M, Luo J. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study. Obesity (Silver Spring). 2023 Feb;31(2):534-544.
Luo J, Feldman R, Rothenberger S, Kortykowski M, Fischer MA, Gellad WF. Incidence and predictors of primary nonadherence to sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 agonists in a large integrated healthcare system. J Gen Intern Med. 2022 Nov;37(14):3562-3569.
Zupa M, Feldman R, Luo J. Trends in out-of-pocket cost of glucagon, 2010-2020. JAMA Netw Open. 2022 Aug 1;5(8):e2229428.
Luo J, Gabriel N, Korytkowski M, Hernandez I, Gellad WF. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. Diabetes Res Clin Pract. 2022 May;187:109855.
- NIH-Forgarty International Clinical Research Scholar, 2009-2010
- Honorable Mention, Hopkins General Internal Medicine Housestaff Research Award, Johns Hopkins School of Medicine, 2013
- First Place, Original Research, Resident Abstract Competition, American College of Physicians (CT Chapter), 2013
